J9308 Ramucirumab - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Ramucirumab

Brand Name:

Cyramza

Strength:

5mg

HCPCS:

J9308

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Monoclonal Antibody

Minor Drug Class:

VEGFR

Oral (Y/N):

No

FDA Approval Year:

2014

FDA Discontinuation Year:

CMS Effective Date:

Jan. 1, 2016

CMS Discontinuation Date:

Status:

In Use